21:45 , Jul 12, 2019 |  BC Extra  |  Company News

July 12 Company Quick Takes: Emflaza could be cost-effective for DMD at highest threshold; plus Darzalex, Skyrizi, Forxiga

ICER gives Emflaza pricing more leeway in updated report  The Institute for Clinical and Economic Review released an updated evidence report on Duchenne muscular dystrophy therapies that increased its range of acceptable prices at which...
02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

BliNK Biomedical financial update

BliNK Biomedical S.A.S. , Lyon, France   Business: Cancer, Antibodies   Date announced: 2016-07-12   Note: BliNK Biomedical raised EUR1.7 million ($1.8 million) in an additional close of a series A round, bringing the total...
07:00 , Oct 12, 2015 |  BioCentury  |  Politics, Policy & Law

Trans-Pacific politics

The biopharma industry is again at the center of a massive political dispute, this time over the Trans-Pacific Partnership. After fighting and losing a battle to persuade or force the rest of the world to...
07:00 , Sep 28, 2015 |  BioCentury  |  Politics, Policy & Law

Goodwill hunting

Martin Shkreli and Hillary Clinton last week provided the flint and steel that ignited a dry tinderbox of well-worn ideas about controlling drug prices. Like all wildfires, the furor flared in the blink of an...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Cancer Research U.K., Kurma Life Sciences Partners S.A. deal

Cancer Research's Cancer Research Technology Ltd. commercial arm and venture capital firm Kurma launched newco BliNK Therapeutics Ltd. to generate therapeutic and diagnostic mAbs. Cancer Research Technology granted BliNK a license to technology that activates...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Financial News

BliNK Therapeutics completes venture financing

BliNK Therapeutics Ltd. , London, U.K.   Business: Antibodies   Date completed: 6/13/11   Type: Venture financing   Raised: Not disclosed   Investor: Kurma Life Sciences Partners   Note: The company received the first of...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

RGN-259: Phase II started

RegeneRx said independent investigators began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 2 drops of RGN-259 given 6 times daily for 28 days in about 20 patients. RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md....
07:00 , Sep 6, 2010 |  BC Week In Review  |  Company News

TearLab, Abbott sales and marketing update

Abbott's AMO Canada Co. subsidiary will promote TearLab's Osmolarity System in Canada, while TearLab will promote AMO's OTC dry eye products. The TearLab Osmolarity System is approved to measure the osmolarity of human tears as...
08:00 , Feb 2, 2009 |  BioCentury  |  Strategy

Genentech gets tenderized

Roche looks to have made a no-lose proposition last Friday when it said it would go directly to Genentech Inc. shareholders with a reduced tender offer for the rest of the biotech giant it doesn't...